Medigen Biotechnology Corp. (TPEX:3176)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.90
+0.05 (0.16%)
Apr 2, 2025, 1:30 PM CST

Medigen Biotechnology Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-204.69-561.3-675.87-52.61-337.92
Upgrade
Depreciation & Amortization
172.31175.77189.13196.35217
Upgrade
Other Amortization
14.132.8721.872.081.84
Upgrade
Loss (Gain) From Sale of Assets
-69.271.03-0.25-19.95
Upgrade
Loss (Gain) From Sale of Investments
-1.449.5816.66-10.922.42
Upgrade
Loss (Gain) on Equity Investments
28.4492.26262.2198.854.57
Upgrade
Stock-Based Compensation
-22.3782.0777.454.87
Upgrade
Provision & Write-off of Bad Debts
6.4814.4421.13-20.49-3.17
Upgrade
Other Operating Activities
86.5-800.48-1,2201,181-545.47
Upgrade
Change in Accounts Receivable
13.8643.35443.69-650.8322.77
Upgrade
Change in Inventory
-97.83145.9260.29-429.02-187.54
Upgrade
Change in Accounts Payable
-0.61-74.3730.853.8339.09
Upgrade
Change in Unearned Revenue
95.374.6-114.03130.511.78
Upgrade
Change in Other Net Operating Assets
-5.3336.49-255.21-58.37-18.49
Upgrade
Operating Cash Flow
37.92-503.52-1,138518.12-687.6
Upgrade
Capital Expenditures
-54.85-38.41-148.16-142.96-132.64
Upgrade
Sale of Property, Plant & Equipment
156.87--12624.65
Upgrade
Sale (Purchase) of Intangibles
-2.17-3.49-3.21-1.59-7.65
Upgrade
Investment in Securities
802.02492.47-2,297-879.7-104.49
Upgrade
Other Investing Activities
1.4247.09-4.54-12.25-16.95
Upgrade
Investing Cash Flow
903.3497.66-2,453-910.5-237.09
Upgrade
Short-Term Debt Issued
118.9210308370412
Upgrade
Long-Term Debt Issued
67.529.71,755-10
Upgrade
Total Debt Issued
186.4239.72,063370422
Upgrade
Short-Term Debt Repaid
-291.7-135.4-280-545-312
Upgrade
Long-Term Debt Repaid
-1,847-28.23-28.91-22.49-471.82
Upgrade
Total Debt Repaid
-2,139-163.63-308.91-567.49-783.82
Upgrade
Net Debt Issued (Repaid)
-1,95276.071,754-197.49-361.82
Upgrade
Issuance of Common Stock
3.43.292.4111.274.45
Upgrade
Repurchase of Common Stock
--18.59---
Upgrade
Other Financing Activities
175.61132.391,734517.572,669
Upgrade
Financing Cash Flow
-1,773193.153,490331.352,311
Upgrade
Foreign Exchange Rate Adjustments
-3.26-5-3.08-0.966.34
Upgrade
Net Cash Flow
-835.21182.29-103.95-621,393
Upgrade
Free Cash Flow
-16.93-541.93-1,286375.16-820.23
Upgrade
Free Cash Flow Margin
-1.23%-46.81%-121.82%9.57%-133.25%
Upgrade
Free Cash Flow Per Share
-0.12-3.89-9.252.70-5.90
Upgrade
Cash Interest Paid
25.2225.6120.119.0731.88
Upgrade
Cash Income Tax Paid
56.0640.2323.358.370.36
Upgrade
Levered Free Cash Flow
27.25-190.22-660.21-246.5-820.31
Upgrade
Unlevered Free Cash Flow
38.82-185.56-654.91-234.58-800.38
Upgrade
Change in Net Working Capital
-42.18-426.28-264.61853.33363.61
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.